索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]王安,王治平,宋丽华.降低脂蛋白a水平的治疗进展[J].国际心血管病杂志,2023,03:151-154.
点击复制

降低脂蛋白a水平的治疗进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2023年03期
页码:
151-154
栏目:
综述
出版日期:
2023-05-30

文章信息/Info

Title:
-
作者:
王安; 王治平; 宋丽华
046013 长治医学院（王安，宋丽华）,046099 长治医学院附属和平医院心内科（王治平）
Author(s):
-
关键词:
脂蛋白a ; 前蛋白转化酶枯草溶菌素9抑制剂; 脂蛋白置换; 反义治疗
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2023.03.007
文献标识码:
-
摘要:
脂蛋白a[Lp（a）]是肝脏合成的一类特殊的脂蛋白颗粒，人Lp（a）水平主要由基因决定，不受饮食、运动的影响。多种药物可降低Lp（a）水平，但目前尚缺乏专门用于降Lp（a）的药物。他汀类及烟酸等药物虽能降低Lp（a）水平，但患者无明显心血管获益。目前正在研发的针对载脂蛋白B（apoB）和载脂蛋白A（apoA）的反义寡核苷酸药物有望成为降低Lp（a）水平、改善心血管预后的药物。
Abstract:
-

参考文献/References

[1] 《中国心血管健康与疾病报告》编写组. 《中国心血管健康与疾病报告2021》概述[J]. 中国心血管病研究, 2022, 20(7):577-596.
[2]Cegla J, Neely RDG, France M, et al. HEART UK consensus statement on Lipoprotein(a): a call to action[J]. Atherosclerosis, 2019, 291:62-70.
[3]Banach M, Penson PE. Statins and Lp(a): do not make perfect the enemy of excellent[J]. Eur Heart J, 2020, 41(1):190-191.
[4]Wang XY, Li JG, Ju JQ, et al. Effect of different types and dosages of statins on plasma lipoprotein(a) levels: a network meta-analysis[J]. Pharmacological Research, 2021, 163:105275.
[5]Tsimikas S, Gordts PLSM, Nora C, et al. Statin therapy increases lipoprotein(a) levels[J]. Eur Heart J, 2020, 41(24):2275-2284.
[6]Akaike MSH, Azuma H, Kagawa A, et al. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases[J]. Clin Chem, 2002, 48(9):1454-1459.
[7] 张华, 张茁. 小剂量阿司匹林对脑血管病患者血清脂蛋白(a)的作用[J]. 北京医学, 2008, 30(2):65-67.
[8]Gencer B, Mach F. Potential of lipoprotein(a)-lowering strategies in treating coronary artery disease[J]. Drugs, 2020, 80(3):229-239.
[9] 滕震, 韦美玉. 阿昔莫司对脂蛋白a治疗效果研究[J]. 健康女性, 2021, 39:144.
[10] Lippi G, Favaloro EJ, Sanchis-Gomar F. Antisense lipoprotein[a] therapy: state-of-the-art and future perspectives[J]. Eur J Intern Med. 2020;76:8-13.
[11] Stulnig TM, Morozzi C, Reindl-Schwaighofer R, et al. Looking at Lp(a) and related cardiovascular risk: from scientific evidence and clinical practice[J]. Curr Atheroscler Rep, 2019, 21(10):37.
[12] Khan TZ, Hsu LY, Arai AE, et al. Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial[J]. Eur Heart J, 2017, 38(20):1561-1569.
[13] 北京心脏学会. 脂蛋白(a)与心血管疾病风险关系及临床管理的专家科学建议[J]. 中国循环杂志, 2021, 36(12):1158-1167.
[14] Awad K, Mikhailidis DP, Katsiki N, et al. Effect of ezetimibe monotherapy on plasma lipoprotein(a) concentrations in patients with primary hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials[J]. Drugs, 2018, 78(4):453-462.
[15] Gaeta G, Lanero SMA, Barra S, et al. Sex hormones and lipoprotein(a) concentration[J]. Expert Opin Investig Drugs, 2011, 20(2):221-238.
[16] Bj?rkegren JLM, Lusis AJ. Atherosclerosis: recent developments[J]. Cell, 2022, 185(10):1630-1645.
[17] Burnap SA, Sattler K, Pechlaner R, et al. PCSK9 activity is potentiated through HDL binding[J]. Circ Res, 2021, 129(11):1039-1053.
[18] Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol[J]. N Engl J Med, 2020, 382(16):1507-1519.
[19] Ruscica M, Greco MF, Ferri N, et al. Lipoprotein(a) and PCSK9 inhibition: clinical evidence[J]. Eur Heart J Suppl, 2020, 22(Suppl L):L53-L56.
[20] O'Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk[J]. Circulation, 2019, 139(12):1483-1492.
[21] Shapiro MD, Minnier J, Tavori H, et al. Relationship between low-density lipoprotein cholesterol and lipoprotein(a) lowering in response to PCSK9 inhibition with evolocumab[J]. J Am Heart Assoc, 2019, 8(4):e010932.
[22] Ray KK, Stoekenbroek RM, Kallend D, et al. Effect of an siRNA therapeutic targeting PCSK9 on atherogenic lipoproteins: prespecified secondary end points in ORION 1[J]. Circulation, 2018, 138(13):1304-1316.
[23] Wright RS, Ray KK, Raal FJ, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis[J]. J Am Coll Cardiol, 2021, 77(9):1182-1193.
[24] Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease[J]. N Engl J Med, 2020, 382(3):244-255.
[25] Fernández-Ruiz I. AKCEA-APO(a)-LRx lowers Lp(a) levels in patients[J]. Nat Rev Cardiol, 2020, 17(3):132.
[26] Nissen SE, Wolski K, Balog C, et al. Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels[J]. JAMA, 2022, 327(17):1679-1687.
[27] Santos RD, Raal FJ, Catapano AL, et al. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase Ⅲ trials[J]. Arterioscler Thromb Vasc Biol, 2015, 35(3):689-699.
[28] Ruscica M, Sirtori CR, Corsini A, et al. Lipoprotein(a):knowns, unknowns and uncertainties[J]. Pharmacol Res, 2021, 173:105812.
[29] Cherepanova OA, Srikakulapu P, Greene ES, et al. Novel autoimmune IgM antibody attenuates atherosclerosis in IgM deficient low-fat diet-fed, but not western diet-fed apoe-/-mice[J]. Arterioscler Thromb Vasc Biol, 2020, 40(1):206-219.
[30] Ferri N, Corsini A, Sirtori CR, et al. Present therapeutic role of cholesteryl ester transfer protein inhibitors[J]. Pharmacol Res, 2018, 128:29-41.
[31] M?kinen P, Ruotsalainen AK, Yl?-Herttuala S. Nucleic acid-based therapies for atherosclerosis[J]. Curr Atheroscler Rep, 2020, 22(2):10.
[32] Crooke ST, Baker BF, Crooke RM, et al. Antisense technology:an overview and prospectus[J]. Nat Rev Drug Discov, 2021, 20(6):427-453.
[33] García-Gómez C, Martín-Martínez MA, Casta?eda S, et al. Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: results from the CARdiovascular in rheuMAtology study project[J]. J Clin Lipidol, 2017, 11(3):749-756.e3.
[34] Shetty A, Hanson R, Korsten P, et al. Tocilizumab in the treatment of rheumatoid arthritis and beyond[J]. Drug Des Devel Ther, 2014, 8:349-364.
[35] Hovingh GK, Klausen IC, Heggen E, et al. Resmetirom (MGL-3196) in patients with heterozygous familial hypercholesterolemia[J]. J Am Coll Cardiol, 2022, 79(12):1220-1222.

备注/Memo

备注/Memo:
通信作者：王治平， E-mail：czhpwzp@163.com
更新日期/Last Update: 2023-05-30